SB
ACLX

Samsara BioCapital’s Arcellx ACLX Stock Holding History

Samsara BioCapital’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99M Hold
60,873
– – 0.68% 15
2025
Q4 		$3.97M Sell
60,873
-20,292
-25% -$1.62M 0.41% 18
2025
Q3 		$6.66M Sell
81,165
-20,292
-20% -$1.46M 0.87% 16
2025
Q2 		$6.68M Sell
101,457
-33,819
-25% -$2.11M 1.37% 12
2025
Q1 		$8.87M Sell
135,276
-118,365
-47% -$8.02M 1.58% 11
2024
Q4 		$19.5M Sell
253,641
-100,000
-28% -$8.64M 2.67% 9
2024
Q3 		$29.5M Sell
353,641
-100,000
-22% -$6.66M 5.68% 6
2024
Q2 		$25M Hold
453,641
– – 5.24% 5
2024
Q1 		$31.6M Sell
453,641
-6,800
-1% -$431K 4.88% 6
2023
Q4 		$25.6M Sell
460,441
-153,480
-25% -$6.92M 3.98% 5
2023
Q3 		$22M Hold
613,921
– – 6.74% 5
2023
Q2 		$19.4M Sell
613,921
-295,658
-33% -$11.3M 3.41% 6
2023
Q1 		$28M Sell
909,579
-47,872
-5% -$1.45M 5.79% 4
2022
Q4 		$29.7M Sell
957,451
-106,384
-10% -$2.44M 6.38% 3
2022
Q3 		$20M Hold
1,063,835
– – 4.66% 6
2022
Q2 		$19.2M Buy
1,063,835
+64,108
+6% +$827K 5.13% 5
2022
Q1 		$14M Buy
+999,727
New +$16.7M 3.53% 8

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Samsara BioCapital's ACLX Position: Q1 2026 in Review

Samsara BioCapital held its Arcellx (ACLX) position steady in Q1 2026 at 60,873 shares worth $6.99M. The position accounts for 0.68% of the portfolio, ranked #15.

Samsara BioCapital first reported a position in ACLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $31.6M in Q1 2024. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Samsara BioCapital held 60,873 shares of Arcellx worth $6.99M as of Q1 2026.
  • Samsara BioCapital left its Arcellx share count unchanged in Q1 2026.
  • Arcellx made up 0.68% of Samsara BioCapital's portfolio in Q1 2026, its #15 holding.
  • Samsara BioCapital first reported a position in Arcellx in Q1 2022 and has held it in 17 quarters since.
  • Samsara BioCapital's Arcellx position peaked at $31.6M in Q1 2024.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.